Skip to main content

Table 1 Summary of phenotypes in whole-lung cells of bleomycin (BLM)- or BLM + pirfenidone-treated mice determined through fluorescence-activated cell sorter analysis in a prophylactic setting *

From: Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis

  Percentage of cells
Treatment CD45-/Col-I- CD45+/Col-I- CD45-/Col-I+ CD45+/Col-I + (Fibrocyte)
Saline 20.5 ± 8.9 51.5 ± 35.6 20.4 ± 25.3 7.5 ± 6.3
BLM 20.1 ± 16.0 21.5 ± 21.8 32.0 ± 6.6 26.5 ± 0.7
BLM + pirfenidone 31.1 ± 13.6 27.3 ± 10.5 19.2 ± 10.7 13.7 ± 6.4
  1. *Data are shown as the percentage of cells that are positive (+) or negative (−) for CD45 or collagen I (Col-I) in whole-lung cells. Data shown represent the means ± standard error from 6 saline-, BLM- or BLM + pirfenidone-treated mice, respectively, and are representative of 2 independent experiments.